Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine plus magnesium sulfate for refractory chronic cluster headache
2020-003604-14Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Refractory Chronic Cluster Headache (rCCH) comparing Ketamine + magnesium sulfate with Hydroxyzine active placebo (2 arms). Primary endpoint: Primary responder rate at days 7-8. Started Dec 2020; status: active.
02
Drugs
ketaminemagnesium sulfate
03
Conditions
Refractory Chronic Cluster Headache (rCCH)
Beyond the preview
Go deeper on 2020-003604-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003604-14.